Latest Pharmaceuticals News

Page 46 of 73
Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.
Ada Torres
Ada Torres
19 Aug 2025
Argenica Therapeutics has received detailed FDA feedback outlining specific data requirements to lift the clinical hold on its ARG-007 stroke trial in the US, setting a clear path forward for its neuroprotective drug.
Ada Torres
Ada Torres
14 Aug 2025
Recce Pharmaceuticals’ RECCE 327 Topical Gel shows statistically significant superiority over standard antibiotics in treating antibiotic-resistant burn wounds in preclinical models, advancing its U.S. Department of Defense collaboration.
Ada Torres
Ada Torres
12 Aug 2025
Island Pharmaceuticals has raised $350,000 through an options exercise by substantial shareholder MWP Partners, reinforcing confidence in its antiviral drug development pipeline.
Ada Torres
Ada Torres
11 Aug 2025
Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.
Ada Torres
Ada Torres
8 Aug 2025
IDT Australia announces the immediate resignation of CEO Paul McDonald, appointing Executive Chair Mark Simari to lead as the company reports a 40.6% revenue increase but a widening net loss for FY25.
Victor Sage
Victor Sage
7 Aug 2025
Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.
Victor Sage
Victor Sage
7 Aug 2025
Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.
Ada Torres
Ada Torres
6 Aug 2025
Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.
Ada Torres
Ada Torres
5 Aug 2025